{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 388986736
| IUPAC_name = 1,2,3,6-Tetrahydro-2,6-dioxo-4-pyrimidinecarboxylic acid
| image = Orotic acid.svg
| width = 150px

<!--Clinical data-->
| tradename = 
| Drugs.com = {{drugs.com|international|orotic-acid}}
| pregnancy_category = 
| legal_status = 
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life =

<!--Identifiers-->
| CASNo_Ref = {{cascite}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 65-86-1
| ATC_prefix = none
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 967
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB02262
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 61H4T033E5
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = C00295
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 942
| smiles            = O=C(O)\C1=C\C(=O)NC(=O)N1
| InChI             = 1/C5H4N2O4/c8-3-1-2(4(9)10)6-5(11)7-3/h1H,(H,9,10)(H2,6,7,8,11)
| InChIKey          = PXQPEWDEAKTCGB-UHFFFAOYAD
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI          = 1S/C5H4N2O4/c8-3-1-2(4(9)10)6-5(11)7-3/h1H,(H,9,10)(H2,6,7,8,11)
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey       = PXQPEWDEAKTCGB-UHFFFAOYSA-N

<!--Chemical data-->
| C=5 | H=4 | N=2 | O=4 
| molecular_weight = 156.10 g/mol
}}

'''乳清酸'''（{{lang-en|'''Orotic acid'''}}，[[共軛鹼|共軛鹼]]作{{lang|en|'''orotate'''}}）或'''嘧啶酸'''（'''{{lang|en|pyrimidinecarboxylic acid}}'''）是一種[[雜環化合物|雜環化合物]]，也是一種有機酸。乳清酸曾經被誤以為是一種[[維生素B|維生素B]]，並被稱為'''{{lang|en|vitamin B<sub>13</sub>}}'''，但後來發現他並不屬於維生素。

此化合物是由[[粒線體|粒線體]]的一種酵素－[[二氫乳清酸脫氫酶|二氫乳清酸脫氫酶]]<ref>{{cite journal | pmid = 10727948 | year = 2000 | author1 = Rawls | first1 = J | title = Requirements for the mitochondrial import and localization of dihydroorotate dehydrogenase | journal = European journal of biochemistry / FEBS | volume = 267 | issue = 7 | pages = 2079–87 | last2 = Knecht | first2 = W | last3 = Diekert | first3 = K | last4 = Lill | first4 = R | last5 = Löffler | first5 = M }}</ref>或細胞質中的{{le|Pyrimidine metabolism|Pyrimidine metabolism|嘧啶合成途徑}}的酵素所合成。有時此化合物會被用做[[乳製品|乳製品]]的{{le|mineral carrier|mineral carrier|礦物質攜帶者}}，如乳清酸鋰。

==合成==
乳清酸可藉由酶將[[4,5-二氢乳清酸|二氫乳清酸]]脫氫形成，之後會與[[磷酸核糖焦磷酸|5'-磷酸核糖焦磷酸]]（PRPP）結合形成[[乳清苷-5'-磷酸|乳清苷-5'-磷酸]]（OMP）。在此時與[[嘌呤代谢#生物合成|嘌呤合成]]的不同點是在與[[核糖|核糖]]相接前，嘧啶環已經完全合成；而嘌呤合成則是將核糖上的鹼基一步一步轉換成嘌呤<ref>{{cite book | author = Lippincott | title = Biochemistry | edition = 4th | date = 2008}}</ref>。

==安全性==
乳清酸為[[哺乳類|哺乳類]]體細胞的[[突變原|突變原]]，同時也可誘變細菌及酵母菌<ref>{{Cite web |url=http://www.sciencelab.com/msds.php?msdsId=9926339 |title=Orotic acid MSDS |access-date=2015-01-25 |archive-date=2016-09-27 |archive-url=https://web.archive.org/web/20160927072216/http://www.sciencelab.com/msds.php?msdsId=9926339 |dead-url=no }}</ref>。

==病理學==
尿中出現乳清酸可能會導致{{le|orotic aciduria|orotic aciduria|乳清酸尿症}}以及[[酸血症|酸血症]]。病因可能是[[Metabolic_disorder|遗传性代谢缺陷]]（如[[Urea_cycle_disorder|尿素循環缺失症]]）導致血液中[[Ammonia|氨]]含量過高。



有一種X染色體關聯[[性聯遺傳|性聯遺傳]]疾病，稱為{{le|ornithine transcarbamoylase deficiency|ornithine transcarbamoylase deficiency|鳥胺酸氨甲醯基轉移酶缺乏症}}，是一種最常見的尿素循環缺失症。此疾病會導致細胞中的[[氨甲酰磷酸|氨甲酰磷酸]]轉化為乳清酸，導致血漿中氨含量過高，尿中乳清酸含量增加，血漿[[Blood_urea_nitrogen|尿素氮]]含量降低。高血氨會導致血漿中的[[α-酮戊二酸|α-酮戊二酸]]含量下降，抑制[[三羧酸循环|三羧酸循环]]及[[三磷酸腺苷|ATP]]產生。

==參見==
*[[名稱獨特的化學物質列表|名稱獨特的化學物質列表]]

==參考文獻==
{{Reflist|2}}

==外部連結==
{{commons|Category:Orotic acid}}
* {{MeshName|Orotic+Acid}}
* {{cite journal | doi = 10.1021/ja01652a056| title = Potential Metabolic Antagonists of Orotic Acid: 6-Uracilsulfonamide and 6-Uracil Methyl Sulfone1| journal = Journal of the American Chemical Society| volume = 76| issue = 23| pages = 6052| year = 1954| last1 = Greenbaum| first1 = Sheldon B.}}

{{Nucleotide metabolism intermediates}}

{{DEFAULTSORT:Orotic Acid}}
[[Category:嘧啶二酮|嘧啶二酮]]
[[Category:羧酸|Category:羧酸]]